Emerging Biomarkers to Consider for NMOSD, Neuromyeltis Optica: Bruce Cree, MD, PhD, MAS, FAAN
November 3rd 2022The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]
Positive Safety Profile of Anti-CD20 Therapy During Postpartum in MS, NMOSD: Riley Bove, MD
November 2nd 2022The associate professor of neurology at the University of California, San Francisco, discussed takeaways from an oral presentation at ECTRIMS 2022 on the use of anti-CD20 therapies in postpartum for patients with MS and NMOSD. [WATCH TIME: 5 minutes]
Ocrelizumab’s Impact on Humoral Response to EBV: Robert Zivadinov, MD, PhD
November 1st 2022The director of the Buffalo Neuroimaging Analysis Center provided context on a new study exploring ocrezliumab’s (Ocrevus; Genentech) effect on leptomeningeal inflammation and humoral response to EBV. [WATCH TIME: 5 minutes]
Capabilities of Stem Cell Transplantation vs Other Relapsing MS Therapies: Tomas Kalincik, MD, PhD
November 1st 2022The professor of neurology and biostatistician at University of Melbourne and Royal Melbourne Hospital spoke on stem cell transplantation in patients with MS and its effectiveness in comparison with other traditional approaches. [WATCH TIME: 2 minutes]
Therapeutic Focuses of MS and the Need to Reach NEDA Status: Stuart Silverman, MD
October 31st 2022As the treatment landscape for relapsing MS continues to strengthen, the neurologist at Allegheny Health Network discussed the reasons for continued pursuit of drug development. [WATCH TIME: 3 minutes]
The Clinical Implications of the ARISE Data in RIS: Darin Okuda, MD
October 28th 2022The director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center shared his perspective on data suggesting that DMT can benefit patients with radiologically isolated syndrome. [WATCH TIME: 3 minutes]
Role of HCPs in Engaging Diverse NMOSD Patient Populations in Clinical Trials
October 28th 2022Mitzi Williams, MD; Mirla Avila, MD; Michael Levy, MD, PhD; and Michael Yeaman, PhD, explore how health care professionals can better engage diverse racial and ethnic groups with NMOSD to improve care and enroll in clinical trials.
Ofatumumab’s Effect on Annualized Relapse Rate in Patients with MS: Jeffrey Cohen, MD
October 28th 2022The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]
MS Field Focused on Slowing Disease Progression: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI
October 27th 2022The senior consultant for the department of neurology at the National Neuroscience Institute discussed his thoughts on improvements in the MS field in relation to this year's ECTRIMS conference. [WATCH TIME: 4 minutes]
Newest Updates in Multiple Sclerosis at ECTRIMS 2022: Tianrong Yeo, MBBS, MRCP, MMED, FAMS, MCI, PhD
October 26th 2022The senior consultant for the department of neurology at the National Neuroscience Institute shares what he looks forward to at this year's ECTRIMS conference. [WATCH TIME: 2 minutes]
IFN 2022 Expands on Neurology Specialties and Positive Brain Health: Stephen Krieger, MD
October 25th 2022The neurologist at the Corinne Goldsmith Dickinson Center for MS offered a brief overview of his experience at the 2022 IFN conference held in New York City on September 23-24. [WATCH TIME: 4 minutes]
Medical Crossfire on the Paradigm Shifts in Migraine Therapy: Jessica Ailani, MD
October 24th 2022The director of the MedStar Georgetown University Hospital Headache Center tells her experience in a medical crossfire as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]